ArticleCurrent drug research reviews2026
Evaluation of Respirable Fraction by using Next Generation Impactor of Levosalbutamol Sulphate and Ipratropium bromide Metered Dose Inhaler.
Article in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA lung condition in which the passage of air into the lungs is obstructed, is treated using a combination pharmaceutical aerosol (Pressurised Metered dosage Inhaler) dosage form, such as Levosalbutamol Sulphate (LS) and Ipratropium Bromide (IB) pressurized inhalation, which contains 50 μg and 20 μg, respectively. Aerodynamic particle size distribution (APSD) aids in comprehending the likelihood of particle deposition in the lungs. In addition to being crucial for the efficacy and safety of medications, the respirable fraction is a significant critical quality attribute (CQA) for nasal and orally inhaled medicinal formulations.
aimsThe evaluation of in-vitro respirable fraction utilizing Next Generator Impactor (NGI) simulates drug particle deposition in the patient's lungs. The current study used a sensitive highpressure liquid chromatography technique to assess the deposited respirable fraction through APSD from NGI, as aerodynamic properties of the delivered dosage. MATERIALS AND
methodsThe samples are subjected to NGI and analyzed on an X-bridge C18 (50 x 4.6), 3.5 μm with 35°C column oven, volume of injection 100 μL, and 0.5 mL per min flow rate using a mobile phase that is a 75:25% v/v combination of Heptane sulphonic acid sodium salt buffer and Acetonitrile in high-pressure liquid chromatography. The designed approach was validated for its anticipated function and determined the respirable fraction of the delivered dose. RESULTS AND DISCUSSION: The respirable fraction (fine particle dose) in μg for Levosalbutamol sulfate and Ipratropium bromide were observed 27.644 ± 1.9 and 11.045 ± 1.8, respectively. The fine particle fraction in percentage for Levosalbutamol sulfate and Ipratropium bromide were observed 55 ± 1.8 and 56 ± 1.8, respectively. There is no method reported for the determination of Levosalbutamol sulphate and Ipratropium bromide from respirable fraction.
conclusionThe reliable results generated by novel combined in-vitro evaluation of LS and IB respirable fractions - correspond to lung deposition in a clinical study, which is about ≤ 5μm particle size in given doses of LS and IB inhalers.
Indexed as
Identifiers
40108911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.